Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Tan Sheet

Executive Summary

Far Ocean Group in deep with FDA; Keystone Labs topicals in violation, according to warning letter; NAD nixes Alde’s antifungal nail polish claim; FDA supplement marketing notice e-submissions in the works; South Korea reorganizes, strengthens its Ministry of Food and Drug Safety.

You may also be interested in...



Health, Natural Claims Can Be Liabilities In Cosmetics Sector – Attorneys

“For the first time you’re seeing personal-care products moving into benefits that really are more about diseases and health conditions,” Jill Bollettieri, assistant general counsel at General Mills, suggested at the Association of National Advertisers’ Advertising Law and Public Policy Conference. Claims for such products, along with natural claims, have their advantages, but firms must exercise caution, attorneys say.

Regulatory News In Brief

Orlistat benefits outweigh risks, EMA says; J&J, Energizer to study SPF 85; Health Canada warns about Miracle Mineral Solution; Regencea recalls RegenArouse; more Regulatory News In Brief

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel